Zollinger‑Ellison syndrome (gastrin‑producing duodenal tumor) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome (Gastrin‑Producing Duodenal Tumor) – Complete Guide

Zollinger‑Ellison Syndrome (Gastrin‑Producing Duodenal Tumor)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by one or more gastrin‑secreting neuroendocrine tumors (often called gastrinomas) that arise most commonly in the duodenum or pancreas. The excess gastrin stimulates the stomach to produce large amounts of acid, leading to severe peptic ulcers, diarrhea, and other gastrointestinal problems.

  • Prevalence: Approximately 1–3 cases per million people per year in the United States, making it an ultra‑rare disease.1
  • Age & gender: Most patients are diagnosed between 30 and 60 years of age; slight male predominance (≈55% male).2
  • Associated conditions: About 25–30% of cases occur as part of Multiple Endocrine Neoplasia type 1 (MEN‑1), a hereditary syndrome that also involves parathyroid and pituitary tumors.3

Symptoms

The clinical picture varies, but most patients experience a combination of the following:

Gastrointestinal symptoms

  • Refractory peptic ulcers: Ulcers that recur despite standard therapy; frequently located in the duodenum, jejunum, or even the esophagus.
  • Abdominal pain: Burning or gnawing pain that may improve after eating (due to buffering of acid) or worsen with fasting.
  • Diarrhea: Occurs in 60–70% of patients; often watery, sometimes greasy, and can lead to dehydration.
  • Steatorrhea (fat malabsorption): Excess acid inactivates pancreatic enzymes, causing fatty stools.
  • Nausea & vomiting: May be triggered by ulcer pain or gastric outlet obstruction.

Systemic symptoms

  • Weight loss: From malabsorption and chronic diarrhea.
  • Fatigue & weakness: Consequence of electrolyte disturbances (e.g., low potassium) and anemia from chronic bleeding.
  • Osteopenia/Osteoporosis: Long‑standing acid hypersecretion can impair calcium absorption.

Signs related to MEN‑1 (if present)

  • Hyperparathyroidism (high calcium levels)
  • Pituitary adenomas (headaches, vision changes, hormonal abnormalities)

Causes and Risk Factors

Primary cause

ZES results from a gastrinoma—a neuroendocrine tumor that secretes gastrin. Most gastrinomas are:

  • Duodenal (≈55%): Located within 2 cm of the ampulla of Vater.
  • Pancreatic (≈30%): Typically in the head of the pancreas.
  • Occult or metastatic (≈15%): Small primary lesion not identified initially; may have spread to the liver or lymph nodes.

Risk factors

  • Genetic predisposition: Inherited MEN‑1 mutation (autosomal dominant) increases risk 10–20‑fold.4
  • Family history of gastrinomas or MEN‑1.
  • Age: Incidence rises after the third decade.
  • Chronic H. pylori infection: Not a direct cause but can exacerbate ulcer disease, masking ZES.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is essential.

Biochemical testing

  • Fasting serum gastrin level: Values > 1,000 pg/mL are highly suggestive; values 2–10× the upper limit with gastric pH < 2 support diagnosis.5
  • Secretin stimulation test: In ZES, gastrin paradoxically rises > 120 pg/mL after IV secretin (normally it falls). This is the gold‑standard functional test.
  • Gastric pH measurement: Persistent acidity (pH < 2) despite PPI therapy indicates acid hypersecretion.

Imaging studies

  • Endoscopic ultrasound (EUS): High‑resolution detection of small duodenal lesions.
  • Multiphasic contrast‑enhanced CT or MRI: Maps tumor size and metastatic spread, especially to liver.
  • Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Sensitive for neuroendocrine tumors; guides surgical planning.
  • Selective arterial secretagogue injection (SASI) test: Rare, used when imaging is inconclusive.

Pathology

If a lesion is resected, histology confirms a neuroendocrine tumor (WHO grade 1–3) with immunohistochemical positivity for gastrin.

Treatment Options

Management combines acid suppression, tumor control, and, when needed, correction of metabolic disturbances.

Acid‑blocking therapy (first line)

  • Proton pump inhibitors (PPIs): High‑dose omeprazole 40 mg BID or equivalent; most patients achieve symptom control.
  • Histamine‑2 receptor antagonists (H2 blockers): May be added for breakthrough symptoms, but PPIs are preferred.
  • PPIs must be continued indefinitely unless the gastrinoma is completely removed and cure is achieved.

Surgical management

  • Curative resection: Enucleation or segmental duodenectomy for localized duodenal gastrinomas; pancreaticoduodenectomy (Whipple) for larger pancreatic lesions.
  • Debulking surgery: When disease is metastatic, removal of > 90% of tumor bulk can improve symptom control and survival.
  • Regional lymphadenectomy: Recommended because up to 60% have nodal spread.

Medical therapies for unresectable or metastatic disease

  • Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin release and may stabilize tumor growth.
  • Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for progressive pancreatic neuroendocrine tumors.
  • Peptide receptor radionuclide therapy (PRRT): ¹⁷⁷Lu‑DOTATATE delivers radiation to somatostatin‑receptor‑positive cells; shown to improve progression‑free survival.
  • Chemotherapy: Reserved for high‑grade (WHO G3) or rapidly progressive disease (e.g., streptozocin‑based regimens).

Lifestyle & supportive care

  • Maintain adequate hydration; oral rehydration solutions if diarrhea is severe.
  • Electrolyte replacement (potassium, magnesium) under medical supervision.
  • Low‑fat diet to reduce steatorrhea.
  • Calcium and vitamin D supplementation to protect bone health.

Living with Zollinger‑Ellison Syndrome (gastrin‑producing duodenal tumor)

Daily management tips

  • Take PPIs exactly as prescribed. Missing doses can precipitate ulcer bleeding.
  • Track bowel movements. Note frequency, consistency, and any blood or mucus.
  • Monitor weight. Unintended loss > 5% in a month warrants evaluation.
  • Regular lab work: Complete blood count, electrolytes, calcium, and gastrin levels every 3–6 months.
  • Scheduled imaging: CT/MRI or PET/CT every 6–12 months to detect recurrence.
  • Vaccinations: If you have had splenectomy or are on immunosuppressive agents for advanced disease, stay up‑to‑date on pneumococcal and influenza vaccines.

Psychosocial considerations

Living with a chronic rare disease can be stressful. Consider the following resources:

  • Patient support groups (e.g., Neuroendocrine Tumor Research Foundation).
  • Counseling or cognitive‑behavioral therapy for anxiety/depression.
  • Financial counseling for medication assistance programs.

Prevention

Because ZES is largely driven by sporadic mutations, primary prevention is limited. However, certain steps can reduce overall risk or detect disease earlier:

  • Genetic counseling: Individuals with a family history of MEN‑1 should undergo germline testing; early surveillance can catch gastrinomas before they become symptomatic.
  • Avoid chronic H. pylori infection: Test and treat according to CDC guidelines; this reduces ulcer burden and may lower diagnostic delay.
  • Healthy lifestyle: Balanced diet, limiting alcohol and NSAID overuse, and smoking cessation help protect the gastric mucosa.

Complications

If untreated or inadequately controlled, ZES can lead to serious outcomes:

  • Gastrointestinal bleeding: From ulcer erosion; may require endoscopic therapy or transfusion.
  • Perforation: A life‑threatening emergency requiring surgery.
  • Malabsorption & severe electrolyte loss: Especially hypokalemia, metabolic alkalosis, and dehydration.
  • Peptic ulcer disease progressing to gastric outlet obstruction.
  • Metastatic neuroendocrine tumor spread: Liver involvement can cause hepatic insufficiency.
  • Bone demineralization: Chronic acid hypersecretion impairs calcium absorption, raising fracture risk.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain with guarding or rigidity (possible ulcer perforation).
  • Vomiting blood (hematemesis) or passing black/tarry stools (melena) indicating gastrointestinal bleeding.
  • Profuse, watery diarrhea leading to dizziness, rapid heartbeat, or fainting (significant dehydration).
  • High fever (> 38.5 °C / 101 °F) combined with abdominal pain (possible infection of a perforated ulcer).
  • New onset confusion, severe weakness, or seizures—possible electrolyte disturbances.

References

  1. Oberg K, et al. Incidence and prevalence of neuroendocrine tumors in the United States. J Clin Oncol. 2008;26(27):4478‑4485. PMID: 18828510.
  2. Mayo Clinic. Zollinger‑Ellison syndrome. Accessed May 2026.
  3. Centers for Disease Control and Prevention. MEN‑1 syndrome. Updated 2024.
  4. National Center for Biotechnology Information. Genetic basis of MEN‑1. 2023.
  5. U.S. National Library of Medicine. Gastrinomas & Zollinger‑Ellison syndrome. Reviewed 2022.
  6. National Comprehensive Cancer Network. Neuroendocrine Tumors Guidelines. Version 2.2024.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References